

January 16, 1970

Dr. Allen P. Berger  
Chas. Pfizer & Co.  
Groton, Connecticut

Dear Allen,

Enclosed is an interim report dated January 4, 1970 of the first phase of the EEG profile analysis of CP 14,368. The report summarizes our observations and concludes with a recommendation that we use 250 mg as the single dose for the phase two studies.

In addition to the summaries and the list of experiments and subjects, I am enclosing the actual data sheets for the behavioral observations. These may be useful to any other investigators who may be interested in the effects of CP 14,368 in normal volunteers. I am also enclosing summary work sheets, insofar as these may be of interest.

Two additional copies of the summary are enclosed for distribution.

The phase two study has begun and should be completed within four months.

Thank you for your cooperation.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp

enc.